Literature DB >> 2294306

Improved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia, 1984 through 1987.

J E Harris1.   

Abstract

I analyzed trends in the survival of 36,847 adults who were diagnosed with acquired immunodeficiency syndrome between January 1984 and September 1987 under the pre-1987 surveillance definition of acquired immunodeficiency syndrome. For patients in whom Pneumocystis carinii pneumonia was among the first manifestations of acquired immunodeficiency syndrome, the estimated 1-year survival increased from 42.7% for those diagnosed in 1984 and 1985 (95% confidence interval, 41.5% to 44.3%) to 54.5% for those diagnosed in 1986 and 1987 (95% confidence interval, 53.7% to 55.7%). The gain in survival was observed in homosexual men and intravenous drug users of both sexes, in all age and racial groups, in all geographic regions, and in patients with and without coexisting initial diagnosis. Reduced mortality in the 3-month period immediately following the initial diagnosis of acquired immunodeficiency syndrome contributed little to the overall gain in survival. No gain in survival was seen for patients in whom P carinii pneumonia was not an initial manifestation of acquired immunodeficiency syndrome. It is unlikely that the observed improvements in survival resulted solely from errors in death reporting. Better diagnosis and treatment, particularly the introduction of zidovudine in 1986, may have contributed to the decline in mortality.

Entities:  

Mesh:

Year:  1990        PMID: 2294306

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  20 in total

1.  Health services needs and related costs for HIV care.

Authors:  D P Andrulis; V B Weslowski
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

2.  Demographic characteristics and survival with AIDS: health disparities in Chicago, 1993-2001.

Authors:  Girma Woldemichael; Demian Christiansen; Sandra Thomas; Nanette Benbow
Journal:  Am J Public Health       Date:  2009-02-12       Impact factor: 9.308

3.  Bleach programs for preventing AIDS among i.v. drug users: modeling the impact of HIV prevalence.

Authors:  J E Siegel; M C Weinstein; H V Fineberg
Journal:  Am J Public Health       Date:  1991-10       Impact factor: 9.308

Review 4.  Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.

Authors:  H D Langtry; K J Palmer; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

5.  Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164.

Authors:  Philip M Grant; Lauren Komarow; Alejandro Sanchez; Fred R Sattler; David M Asmuth; Richard B Pollard; Andrew R Zolopa
Journal:  HIV Clin Trials       Date:  2014 Jul-Aug

Review 6.  Clinical aspects of HIV infection in women.

Authors:  G O Coodley; M K Coodley; A F Thompson
Journal:  J Gen Intern Med       Date:  1995-02       Impact factor: 5.128

7.  Prognostic factors of early fatal outcome and long-term survival in patients with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome.

Authors:  A Antinori; G Maiuro; F Pallavicini; F Valente; G Ventura; G Marasca; R Murri; E Pizzigallo; G Camilli; E Tamburrini
Journal:  Eur J Epidemiol       Date:  1993-03       Impact factor: 8.082

8.  Clinical research, prophylaxis, therapy, and care for HIV disease in Africa.

Authors:  K M De Cock; S B Lucas; S Lucas; J Agness; A Kadio; H D Gayle
Journal:  Am J Public Health       Date:  1993-10       Impact factor: 9.308

9.  Patterns of primary care of patients infected with human immunodeficiency virus.

Authors:  M D Wenrich; P G Ramsey
Journal:  West J Med       Date:  1991-10

10.  Survival with AIDS in Massachusetts, 1979 to 1989.

Authors:  G R Seage; S Oddleifson; E Carr; B Shea; L Makarewicz-Robert; M van Beuzekom; A De Maria
Journal:  Am J Public Health       Date:  1993-01       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.